If your question is a gambling related question, I would expect to be a slight net seller going forward in the short term until the market adjusts itself. I expect the market to be quick on their re-evaluation on the Blue Jays when they start regressing, as the premium has not been terribly high during their upswing.
<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com
ffice
ffice" /><o
></o
>
In reality, what the we are dealing with in regards to the Blue Jays is a slightly above average to good team- a team built to win 81-85 games. The concerning part about their recent run is that it has been heavily dependent on their lineup- a lineup that in reality is below average, and not one of the top lineups in the league that current performance would suggest. Four to five of their starting hitters are performing at least one standard deviation above their true predictive performance, 3 of which are veteran players that are on the downward end of their careers and have very predictive performances metrics. Expect severe regression in their lineup, sooner, rather than later.
<o
></o
>
The question is can their starting pitching and bullpen overcome the expected regression in their hitting. The answer is probably not. The injuries to Marcum and McGowan at the beginning of the year is very material, and probably the difference between being able to make the playoffs, and once again ending their season after 162 games. Their backend of their rotation is filled with a lot of “no-name” young, unproven pitchers. However, in reality, they have a lot of upside and their true worth is probably slightly higher than what the market expect them to be. The bad news is these arms are not built nor proven to pitch in a 162 game season, so second half regression should be expected and quantified into their lines. So from a gambling perspective the time to “buy” into their young arms is the next couple of months, which happens to coincide with “selling” their lineup.
<o
></o
>
The bullpen, like it has been the last two years, is where their true worth lies. Getting Ryans out of the closing role should add value. More importantly, their bullpen is not top heavy, instead very deep, an asset that will be able to offset their young arms inability to eat up innings. Bullpens in general are typically not fully valued by the market, so hidden value lies with this facet of their game.
<o
></o
>
The bottom line is not to expect current performance to last much longer. Their lineup can not sustain such a feat. Coupled with expected increase productivity from the Rays and Yankees, and there is enough downward pressure on the Blue Jays to proceed with caution and to expect to be a net seller in the short term.